Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery.JAMA. 2017; 317: 1642-1651
- Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization.Circulation. 2018; 137: 1221-1232
- Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis.Anesthesiology. 2011; 114: 796-806
- Myocardial Injury After Noncardiac Surgery: A Systematic Review and Meta-Analysis.Cardiol Rev. 2019; 27: 267-273
- Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes.Anesthesiology. 2014; 120: 564-578
- Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery.The Canadian journal of cardiology. 2017; 33: 17-32
- Fourth Universal Definition of Myocardial Infarction (2018).Journal of the American College of Cardiology. 2018; 72: 2231-2264
- Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery.Jama. 2012; 307: 2295-2304
- High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers.Clinical chemistry and laboratory medicine. 2019; 57: 623-632
- Methods for categorizing a prognostic variable in a multivariable setting.Statistics in medicine. 2003; 22: 559-571
- Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.Statistics in medicine. 2000; 19: 113-132
- Predicting Myocardial Injury and Other Cardiac Complications After Elective Noncardiac Surgery with the Revised Cardiac Risk Index: The VISION Study.The Canadian journal of cardiology. 2021; 37: 1215-1224
- The Silent Burden of Perioperative Myocardial Infarction After Noncardiac Surgery.The Canadian journal of cardiology. 2021; 37: 188-190
- Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.Lancet (London, England). 2018; 391: 2325-2334
- Myocardial Injury after Noncardiac Surgery and Perioperative Atrial Fibrillation: From Evidence to Clinical Practice.Can Journ Gen Int Med [Internet. 2021; 16: 18-26
- Troponin T or troponin I as cardiac markers in ischaemic heart disease.Heart (British Cardiac Society). 2000; 83: 371
- Underutilization of Perioperative Screening for Cardiovascular Events After Noncardiac Surgery in Alberta.The Canadian journal of cardiology. 2021; 37: 57-65
- Prognostic Role of High-sensitivity Cardiac Troponin I and Soluble Suppression of Tumorigenicity-2 in Surgical Intensive Care Unit Patients Undergoing Non-cardiac Surgery.Ann Lab Med. 2018; 38: 204-211
- Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery.Circulation. 1999; 100: 1043-1049
- Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review.Jama. 2014; 311: 2181-2190
- Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial.British journal of anaesthesia. 2015; 115: 227-233
Association between complications and death within 30 days after noncardiac surgery. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2019;191:E830-e7.
- Letter by Hwang et al Regarding Article, “Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans”.Circulation. 2021; 144: e166-e167
- Clinical Validation of a Novel High-Sensitivity Cardiac Troponin I Assay for Early Diagnosis of Acute Myocardial Infarction.Clinical chemistry. 2018; 64: 1347-1360
Publication stageIn Press Journal Pre-Proof
In a prospective cohort of 3953 adults who had in-hospital noncardiac surgery, a postoperative hs-cTnI ≥60 ng/L measured within the first three postoperative days was associated with a >7-fold increase in the risk of subsequent major cardiac events or mortality at 30 days. In patients with hs-cTnI ≥60 ng/L, the incidence of major cardiac events or 30-day mortality was 10.0% compared to 1.0% in patients with hs-cTnI <60 ng/L.
The overall VISION Study was funded by >70 grants and funding sources. Abbott Laboratories provided the hs-cTnI assays and some funding for the analysis. No funding entity had a role in data collection, statistical analysis, manuscript writing, or decision to publish.
ED reports investigator-initiated research grants, lecture fee, and honoraria for advisory board participation from Roche Diagnostics, and investigator-initiated research grants from Abbott Diagnostics. FKB reports investigator-initiated research grant from Siemens Healthcare Diagnostics and Roche Diagnostics. PK has received grants, reagents, consultant, advisor, honoraria from Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Ortho Clinical Diagnostics, Randox Laboratories, Roche Diagnostics, Quidel, Siemens Healthcare Diagnostics and Thermo Fisher Scientific. McMaster University has filed patents with Dr. Kavsak listed as an inventor in the acute cardiovascular biomarker field. RP RP has received research grants and/or honoraria from Edwards Lifesciences, Intersurgical and GloaxoSmithkline. CM reports research grants from Swiss National Science Foundation, grants from Swiss Heart Foundation, support from University Hospital Basel, the University of Basel, Novartis, Abbott, Beckman, Roche Diagnostics, Novartis, Singulex, BRAHMS, Quidel, Mitsubishi, Ortho Clinical, Siemens, Astra Zeneca, and Boehringer Ingelheim, all outside the submitted work. PJD is a member of a research group with a policy of not accepting honorariums or other payments from industry for their own personal financial gain. They do accept honorariums/payments from industry to support research endeavours and costs to participate in meetings. Based on study questions PJD has originated and grants he has written, he has received grants from Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb, CloudDX, Coviden, Octapharma, Philips Healthcare, Roche Diagnostics, Siemens and Stryker. PJD has participated in advisory board meetings for GlaxoSmithKline, Boehringer Ingelheim, Bayer and Quidel Canada. He attended an expert panel meeting with AstraZeneca and Boehringer Ingelheim and he was Consultant for a call with Roche Pharma and consultant work with Trimedic. He has also been invited as a speaker with Bayer Inc and Novartis Pharma Canada. All other authors have no conflict to disclose.